Seres therapeutics reports fourth quarter and full year 2024 financial results and provides business updates

Recent fda feedback received on ser-155 allogeneic hematopoietic stem cell transplant (allo-hsct) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (bsis) at day 30 post-hsct; company expects to submit draft study protocol to fda in q2 2025
mcrb Ratings Summary
mcrb Quant Ranking